A Crystal Ball For Drug Launch Success? Try Consensus Estimates
This article was originally published in The Pink Sheet Daily
Consensus estimates can be a predictor of how a biopharma will perform during a drug launch, a Leerink Swann report shows, citing examples from the last ten years as proof.
You may also be interested in...
Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.